Curanex Pharmaceuticals(CURX.US)

Curanex Pharmaceuticals Sets CFO Compensation at $20,000 Per Year

Curanex Pharmaceuticals Inc. has appointed Wanjun Zhang as the new CFO and Treasurer, effective January 1, 2026, following Haiyan Yang's resignation. Zhang will receive an annual compensation of $20,000 under a two-year consulting agreement. This announcement was published via EDGAR by the U.S. SEC.

Curanex Pharmaceuticals Delays Quarterly Financial Report

Curanex Pharmaceuticals Inc. has announced a delay in filing its quarterly financial report for the period ending September 30, 2025. The company cited the need for more time to avoid unreasonable effort or expense and plans to file within the allowed extension period. The original announcement was made via the EDGAR system on November 17, 2025.

Curanex Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

Curanex Pharmaceuticals Faces Nasdaq Delisting Warning

Curanex Pharmaceuticals Inc. (CURX) has received a warning from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has until May 4, 2026, to address this issue, with a possible 180-day extension. Non-compliance may lead to delisting from the Nasdaq Capital Market. Curanex is a Nevada-based pharmaceutical company focused on developing pharmaceutical products.

Curanex Pharmaceuticals Receives Nasdaq Delisting Warning for Low Share Price

Curanex Pharmaceuticals Inc. has received a Nasdaq delisting warning due to its stock closing below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 4, 2026, to regain compliance by maintaining the required price for ten consecutive days. Curanex's stock will continue to trade under the symbol "CURX" during this period, and it may be eligible for an additional 180-day extension if compliance is not achieved.